Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2024-05-14 00:00:00 ET · period of report 2024-05-13 · accession 0000950170-24-059506 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-05-14 | 2024-05-13 | LXEO | Townsend Richard Nolan | CEO, Dir | S - Sale+OE | $13.22 | -5,000 | 170.7K | -3% | -$66.1K |
| DT | 2024-05-14 | 2024-05-13 | LXEO | Townsend Richard Nolan | CEO, Dir | M - OptEx | $2.33 | +5,000 | 175.7K | +3% | +$11.7K |
| DT | 2024-05-14 | 2024-05-13 | LXEO | Townsend Richard Nolan | CEO, Dir | M - OptEx | $2.33 | -5,000 | 148.7K | -3% | -$11.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-13 | S | D | 5,000 | $13.22 | 170,695 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $12.98 to $13.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| 2 | Common | Common Stock | 2024-05-13 | M | A | 5,000 | $2.33 | 175,695 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-05-13 | M | D | 5,000 | $2.33 | 148,655 | D | $2.33 · — to 2031-02-15 | 5,000 Common Stock | (F4) 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |